

Laboratory Service Report

1-800-533-1710

Patient Name	Patient ID	Age		Order #
SAMPLEREPORT, DRD3 A	SA00059536	47	F	SA00059536
Ordering Phys				DOB
CLIENT, CLIENT				06/10/1966
Client Order #	Account Information			Report Notes
SA00059536				
Collected	C7028846-DLMP Rochester			
06/27/2013 00:00	3050 Superior Drive			
Printed	Rochester, MN 55901			
09/17/2013 07:31				

Test Flag Results Unit Value Site*

DRD3 Genotype

MCR

RECEIVED: 07/03/2013 13:33 REPORTED: 09/16/2013 17:45
Homozygous DRD3 25G/25G [glycine/glycine]. This individual is homozygous for the DRD3 25G allele which encodes for the glycine/glycine genotype. The glycine allele is associated with better response to clozapine and olanzapine but a poorer response to risperidone than other genotypes. The glycine allele has also been associated with higher risk of development of tardive dyskinesia after use of typical antipsychotics.

Direct polymorphism analysis of the DRD3 25A>G [Ser9Gly] polymorphism is performed by allele specific primer extension assay following PCR amplification. This DNA testing will not detect all the known mutations and polymorphisms of DRD3. Historically, the SNP is located at position 25 of the cDNA. However, more recent work indicates it is position 456 of the cDNA. Absence of mention of a specific gene mutation or polymorphism does not rule out the possibility that a patient has that or another variation that can impact the function of this receptor, drug response or drug side effects. Laboratory developed test.

Reviewed by Jamie Bruflat

MCR

* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus	Lab Director: Franklin R. Cockerill, III, M.D.
_	200 First St SW Rochester, MN 55905	, ,

Patient Name	Collection Date and Time	Report Status
SAMPLEREPORT,DRD3 A	06/27/2013 00:00	Final
Page 1 of 1		** End of Report **

^{*} Report times for Mayo performed tests are CST/CDT